Menu
Not yet recruiting NCT04954989

Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers

Phase I Interventional Healthy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU, Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU.
Who it may be relevant to
Registry conditions: Healthy. Basic parameters: 18 years — 55 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
India
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Phase I Open and Monocentric Clinical Trial With Pharmacokinetic and Pharmacodynamic Determination of Intravenous Recombinant Human Erythropoietin in Male Adults.

Overview

Open label and monocentric Phase I Clinical Trial, to Determine the Pharmacokinetics and Pharmacodynamics of Recombinant Human Erythropoietin for Subcutaneous Use in an Adult Male Population

Detailed description

An open label, balanced, randomized, two treatments, two sequences, two periods, single dose, crossover design will be used to study the pharmacokinetics and pharmacodynamics of two different rHuEpo products when administered subcutaneously in healthy subjects.

PK parameters to evaluate shall be AUCt and AUCt to infinity, and Cmax PD parameter shall be erithrocye and reticulocyte counts and hematocrite. Bioequivalence shall be evaluated according to 80-125 T/R rate for 90 % Cmax and AUC for pk and PD parameters.

Interventions

  • Biological Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU
    Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously
  • Biological Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU
    Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) should be administered subcutaneously

Primary outcome measures

  • Evaluation of AUC0-inf [Time frame: 14 days]
  • Evaluation Cmax [Time frame: 14 days]
  • Evaluation of Emax [Time frame: 14 days]
  • Evaluation of ASEC0-t [Time frame: 14 days]
Secondary outcome measures (2)
  • half life [Time frame: 14 days]
  • Tmax [Time frame: 14 days]

Eligibility criteria

Inclusion criteria

  • Healthy eligible participants able to read, understand and sign the latest version of the Informed Consent Form (FICF) approved by the Research Ethics Committee (CEP);
  • Male participants aged between 18 and 55 years;
  • Be characterized as a healthy research participant, based on medical history, general physical examination and vital signs, laboratory tests and ECG not indicating any evidence of disease;
  • Present BMI ≥ 18 and ≤ 29.9 Kg/m2;
  • Have a body weight of 60 - 100 kg;
  • Present a negative test for coronavirus.

Exclusion criteria

  • Present one or more flu-like symptoms such as: fever (body temperature greater than or equal to 37.8°C), cough, dyspnea, myalgia and fatigue, respiratory symptoms, gastrointestinal symptoms (such as diarrhea) within 7 days prior to the hospital stay (all periods);
  • Having had direct and significant contact, at the medical discretion, with people who tested positive for a coronavirus test within 14 days prior to the hospital stay (all periods);
  • Living in the same household as people who fall into the risk group of worse prognosis for coronavirus infection, such as individuals over 60 years old, individuals with respiratory problems, immunosuppressed or those with chronic diseases such as heart or diabetes (all periods );
  • Any clinical condition or laboratory alteration that, at the investigator's discretion, may compromise trial participation, ie:
  • Have an abnormal erythrocyte count (<4.0 M/mm3 or >5.4 M/mm3);
  • Have an abnormal reticulocyte count (> 3.0%);
  • Have an abnormal platelet count (< 135,000/μL or > 550,000/μL);
  • Have an abnormal hemoglobin level (< 13g/dL);
  • Have an abnormal level of hematocrit (<40% or >54%);
  • Have an abnormal level of ferritin (< 100 ng/mL or > 336.2 ng/mL);
  • Have an abnormal level of transferrin (< 200 mg/dL or > 360 mg/dL);
  • Have an abnormal level of transferrin saturation (<20%)
  • Have abnormal levels of vitamin B12 (< 130 pg/mL or >868 pg/mL);
  • Present evidence of cardiovascular disorders, particularly arterial hypertension (supine blood pressure > 145 / 90mmHg at baseline);
  • History of venous thrombosis;
  • Participants diagnosed with iron deficiency anemia or clinical history of autoimmune or hereditary anemia;
  • Clinical history of chronic or acute hemorrhages in the 30 days preceding the start of the trial;

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Open label
Primary purpose
Treatment

Study locations

India · 1 center
  • Azidus Laboratories — Chennai

Identifiers

NCT: NCT04954989 · RUBI

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗